Neutralizing antibodies in the intestinal mucosa are essential to control gastrointestinal infection by Shiga toxin-producing Escherichia coli

Abstract

Infections with Shiga toxin (Stx)-producing Escherichia coli (STEC) strains can result in a wide range of clinical presentations. Despite STEC O157:H7 being the serotype most frequently associated with hemolytic uremic syndrome (HUS), in some patients, a self-limited gastrointestinal infection is observed. We have previously demonstrated that genetic differences between BALB/c and C57BL/6 mice account for a different outcome after an experimental gastrointestinal STEC O157:H7 infection, in which the better outcome observed in BALB/c mice was associated with a Th-2 biased immune response. The objective of this study was to determine the role of anti-STEC antibodies during STEC O157:H7 infections. We first demonstrated that the B-cell-dependent response triggered upon STEC O157:H7 infection is necessary to keep BALB/c mice healthy and reciprocally C57BL/6 mice pre-challenged with an Stx2-deficient STEC O157:H7 strain were able to survive, remaining healthy after a subsequent STEC O157:H7 infection. We further proved that anti-STEC O157:H7 antibodies raised after infection have binding specificity against STEC O157:H7 bacteria, recognize H7, and have neutralizing capacitiy, by interfering with important pathogenic mechanisms such as motility and adhesion to intestinal epithelial cells. We conclude that local and/or systemic specific antibodies against STEC mediate prevention of lethal complications during STEC O157:H7 infections.

Keywords

antibodies / gastrointestinal infection / HUS / mouse model / STEC

References

[1] Pianciola L, Rivas M. Genotypic features of clinical and bovine Escherichia coli O157 strains isolated in countries with different associated-disease incidences. Microorganisms. 2018; 6: 36.

[2] Bruyand M, Mariani-Kurkdjian P, Gouali M, de Valk H, King LA, Le Hello S, et al. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect. 2018; 48: 167-174.

[3] Ylinen E, Salmenlinna S, Halkilahti J, Jahnukainen T, Korhonen L, Virkkala T, et al. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome. Pediatr Nephrol. 2020; 35: 1749-1759.

[4] Pitiot A, Ferreira M, Parent C, Boisseau C, Cortes M, Bouvart L, et al. Mucosal administration of anti-bacterial antibodies provide long-term cross-protection against Pseudomonas aeruginosa respiratory infection. Mucosal Immunol. 2023; 16: 312-325.

[5] Ye J, Shao H, Hickman D, Angel M, Xu K, Cai Y, et al. Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin Vaccine Immunol. 2010; 17: 1363-1370.

[6] Lambour J, Naranjo-Gomez M, Piechaczyk M, Pelegrin M. Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play. Emerg Microbes Infect. 2016; 5: e92.

[7] Mayor A, Thibert B, Huille S, Bensaid F, Respaud R, Audat H, et al. Inhaled IgG1 antibodies: the buffering system is an important driver of stability during mesh-nebulization. Eur J Pharmaceut Biopharmaceut. 2022; 181: 173-182.

[8] Respaud R, Marchand D, Pelat T, Tchou-Wong K-M, Roy CJ, Parent C, et al. Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin. J Control Release. 2016; 234: 21-32.

[9] Hiriart Y, Scibona P, Ferraris A, Belloso WH, Beruto V, Garcia Bournissen F, et al. A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab′)₂ fragments in healthy volunteers. Br J Clin Pharmacol. 2024; 90: 1142-1151.

[10] Ma Z, Kang M, Meng S, Tong Z, Yoon S-D, Jang Y, et al. Selective killing of shiga toxin-producing Escherichia coli with antibody-conjugated chitosan nanoparticles in the gastrointestinal tract. ACS Appl Mater Interfaces. 2020; 12: 18332-18341.

[11] Mejías MP, Hiriart Y, Lauché C, Fernández-Brando RJ, Pardo R, Bruballa A, et al. Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS). Sci Rep. 2016; 6: 24913.

[12] Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6: 148-158.

[13] Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine. 2012; 30: 142-154.

[14] Bernal AM, Fernández-Brando RJ, Bruballa AC, Fiorentino GA, Pineda GE, Zotta E, et al. Differential outcome between BALB/c and C57BL/6 mice after Escherichia coli O157:H7 infection is associated with a dissimilar tolerance mechanism. Infect Immun. 2021; 89: e00031-21.

[15] Mohawk KL, O'Brien AD. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. J Biomed Biotechnol. 2011; 2011: 258185.

[16] Ritchie JM. Animal models of enterohemorrhagic Escherichia coli infection. Microbiol Spectr. 2014; 2: EHEC-0022-2013.

[17] Girón JA, Torres AG, Freer E, Kaper JB. The flagella of enteropathogenic Escherichia coli mediate adherence to epithelial cells. Mol Microbiol. 2002; 44: 361-379.

[18] Eckmann L, Stappenbeck TS. IgG “detoxes” the intestinal mucosa. Cell Host Microbe. 2015; 17: 538-539.

[19] Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, et al. Human neonatal FC receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity. 2004; 20: 769-783.

[20] Sun H, Wang M, Liu Y, Wu P, Yao T, Yang W, et al. Regulation of flagellar motility and biosynthesis in enterohemorrhagic Escherichia coli O157:H7. Gut Microbes. 2022; 14: 2110822.

[21] Imdad A, Mackoff SP, Urciuoli DM, Syed T, Tanner-Smith EE, Huang D, et al. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021; 7: CD012997.

[22] Simmons CP, Clare S, Ghaem-Maghami M, Uren TK, Rankin J, Huett A, et al. Central role for B lymphocytes and CD4⁺ T cells in immunity to infection by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun. 2003; 71: 5077-5086.

[23] Mejias MP, Ghersi G, Craig PO, Panek CA, Bentancor LV, Baschkier A, et al. Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and brucella lumazine synthase confers total protection against higa toxins in mice. J Immunol. 2013; 191: 2403-2411.

[24] Martorelli L, Garimano N, Fiorentino GA, Vilte DA, Garbaccio SG, Barth SA, et al. Efficacy of a recombinant Intimin, EspB and Shiga toxin 2B vaccine in calves experimentally challenged with Escherichia coli O157:H7. Vaccine. 2018; 36: 3949-3959.

[25] Shekar A, Ramlal S, Jeyabalaji JK, Sripathy MH. Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice. Med Microbiol Immunol. 2019; 208: 89-100.

[26] Mantis NJ, Rol N, Corthésy B. Secretory IgA's complex roles n immunity and mucosal homeostasis in the gut. Mucosal Immunol. 2011; 4: 603-611.

[27] Wen Y, Mu L, Shi Y. Immunoregulatory functions of immune complexes in vaccine and therapy. EMBO Mol Med. 2016; 8: 1120-1133.

[28] Kadaoui KA, Corthésy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol. 2007; 179: 7751-7757.

[29] Bernal AM, Sosa FN, Todero MF, Montagna DR, Vermeulen ME, Fernández-Brando RJ, et al. Nasal immunization with H7 flagellin protects mice against hemolytic uremic syndrome secondary to Escherichia coli O157:H7 gastrointestinal infection. Front Cell Infect Microbiol. 2023; 13: 1143918.

[30] McNeilly TN, Naylor SW, Mahajan A, Mitchell MC, McAteer S, Deane D, et al. Escherichia coli O157:H7 colonization in cattle following systemic and mucosal immunization with purified H7 flagellin. Infect Immun. 2008; 76: 2594-2602.

[31] Nempont C, Cayet D, Rumbo M, Bompard C, Villeret V, Sirard J-C. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol. 2008; 181: 2036-2043.

[32] Pfister SP, Schären OP, Beldi L, Printz A, Notter MD, Mukherjee M, et al. Uncoupling of invasive bacterial mucosal immunogenicity from pathogenicity. Nat Commun. 2020; 11: 1978.

[33] Mahajan A, Currie CG, Mackie S, Tree J, McAteer S, McKendrick I, et al. An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157: H7 with bovine intestinal epithelium. Cell Microbiol. 2009; 11: 121-137.

[34] McWilliams BD, Torres AG. Enterohemorrhagic Escherichia coli adhesins. Microbiol Spectr. 2014; 2: EHEC-0003-2013.

[35] Khani M-H, Bagheri M, Zahmatkesh A, Aghaiypour K, Mirjalili A. Effect of flagellin on inhibition of infectious mechanisms by activating opsonization and salmonella flagellum disruption. Microb Pathog. 2020; 142: 104057.

[36] Cullender TC, Chassaing B, Janzon A, Kumar K, Muller CE, Werner JJ, et al. Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut. Cell Host Microbe. 2013; 14: 571-581.

[37] Suzuki K, Nakajima A. New aspects of IgA synthesis in the gut. Int Immunol. 2014; 26: 489-494.

[38] Moor K, Diard M, Sellin ME, Felmy B, Wotzka SY, Toska A, et al. High-avidity IgA protects the intestine by enchaining growing bacteria. Nature. 2017; 544: 498-502.

[39] Slack E, Diard M. Resistance is futile? Mucosal immune mechanisms In the context of microbial ecology and evolution. Mucosal Immunol. 2022; 15: 1188-1198.

[40] Suzuki K. Diversified IgA-bacteria interaction in gut homeostasis. Adv Exp Med Biol. 2020; 1254: 105-116.

[41] Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001; 410: 1099-1103.

[42] Karpman D, Békássy ZD, Sjögren A-C, Dubois MS, Karmali MA, Mascarenhas M, et al. Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. Pediatr Nephrol. 2002; 17: 201-211.

[43] Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med. 2017; 281: 123-148.

[44] Amigo N, Mercado E, Bentancor A, Singh P, Vilte D, Gerhardt E, et al. Clade 8 and clade 6 strains of Escherichia coli O157:H7 from cattle in Argentina have hypervirulent-like phenotypes. PLoS One. 2015; 10: e0127710.

[45] Brando RJF, Miliwebsky E, Bentancor L, Deza N, Baschkier A, Ramos MV, et al. Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains. Clin Exp Immunol. 2008; 153: 297-306.

[46] Fernandez-Brando RJ, McAteer SP, Montañez-Culma J, Cortés-Araya Y, Tree J, Bernal A, et al. Mechanisms involved in the adaptation of Escherichia coli O157:H7 to the host intestinal microenvironment. Clin Sci. 2020; 134: 3283-3301.

[47] Albanese A, Gerhardt E, García H, Amigo N, Cataldi A, Zotta E, et al. Inhibition of water absorption and selective damage to human colonic mucosa induced by Shiga toxin-2 are enhanced by Escherichia coli O157:H7 infection. Int J Med Microbiol. 2015; 305: 348-354.

[48] Assensi V, Himeno K, Kawamura I, Sakumoto M, Nomoto K. In vivo influence of the anti-B220 monoclonal antibody administration on the T cell differentiation in mice. Microbiol Immunol. 1989; 33: 329-339.

[49] Miranda MCG, Oliveira RP, Torres L, Aguiar SLF, Pinheiro-Rosa N, Lemos L, et al. Frontline science: abnormalities in the gut mucosa of non-obese diabetic mice precede the onset of type 1 diabetes. J Leukoc Biol. 2019; 106: 513-529.

[50] Mejias MP, Cabrera G, Fernández-Brando RJ, Baschkier A, Ghersi G, Abrey-Recalde MJ, et al. Protection of mice against Shiga toxin 2 (Stx2)-associated damage by maternal immunization with a Brucella lumazine synthase-Stx2 B subunit chimera. Infect Immun. 2014; 82: 1491-1499.

[51] National Research Council. Guide for the care and use of laboratory animals. 8th ed. Washington, DC: National Academies Press (US); 2011.

RIGHTS & PERMISSIONS

2025 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.